Previous 10 |
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the promotion of Ben Palleiko to Chief Business Officer in addition to his current role a...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Buy rating and $35 (24% upside) price target at Needham. More news on: KalVista Pharmaceuticals, Inc., ResMed Inc., Nevro Corp., Healthcare stocks news, Stocks on the move, , Read more ...
Gainers: Atossa Genetics (NASDAQ: ATOS ) +242% . Hancock Jaffe Laboratories (NASDAQ: HJLI ) +41% . WageWorks (NYSE: WAGE ) +30%. Smith Micro Software (NASDAQ: SMSI ) +31% . Akari Therapeutics (NASDAQ: AKTX ) +30% . KalVista Pharmaceuticals (NASDAQ: KALV ) +29% . MongoDB (NASDA...
– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...
– KVD900 600 mg Provides >90% Inhibition of Plasma Kallikrein Within 30 Minutes of Dosing – – Single 600 mg Dose of KVD900 Provides Protection of HK Cleavage for at Least 10 Hours – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Brian Pereira has been appointed to its Board of Directors effective February 1, 201...
NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TechnipFMC plc (NYSE:FTI), Glu Mobile Inc. (NASDAQ:GLUU), EPR Properti...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...